Compare Charles River Laboratories Intl. Inc (CRL) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Marathon Petroleum Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $229.26 (market cap $11.14B), while Marathon Petroleum Corp trades at $297.81 (market cap $88.57B). The key difference: Marathon Petroleum Corp is far larger — about 8× Charles River Laboratories Intl. Inc's market cap, and Marathon Petroleum Corp pays a 1.29% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MPC | |
|---|---|---|
Market Cap | $11.14B | $88.57B |
Sector | Health | Energy |
52-Week High | $233.60 | $303.40 |
52-Week Low | $145.57 | $158.59 |
Enterprise Value | $14.00B | $120.75B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today and near its 52-week high. The stock shows strong momentum with bullish moving averages and a consensus analyst rating of Buy (75.76%). Recent earnings beat expectations in Q4 2025 and Q1 2026, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. The company maintains solid profitability with a 3.42% net margin and 27.92% ROE, supported by a dividend payment of $1.00 scheduled for June 2026.
MPC's outlook is positive due to elevated refining margins and analyst optimism, but risks include volatile oil prices, legal challenges over AI pricing allegations, and declining revenue trends. The stock trades above the consensus price target of $292.70, suggesting limited near-term upside despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
